Buprenorphine Combination Tablet Feasibility - 1
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00000298 |
Recruitment Status :
Completed
First Posted : September 21, 1999
Last Update Posted : August 17, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Opioid-Related Disorders | Drug: Buprenorphine/naloxone | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 0 participants |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Buprenorphine Combination Tablet Feasibility |
Study Start Date : | August 1995 |

- Withdrawal symptoms
- Opiate use
- Opiate craving

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Males/Females ages 21-50, opiate dependence according to DSM-IV criteria, self-reported use within the last 30 days, agreeable to conditions of study and signed informed consent
Exclusion Criteria:
Psychiatric disorder that requires medication therapy, history of seizures, pregnant and/or nursing women, dependence on etoh or benzodiazepines or other sedative-hypnotics, acute hepatitis, other medical conditions that deem participation to be unsafe.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000298
United States, California | |
Friends Research Institute | |
Los Angeles, California, United States, 90025 |
Principal Investigator: | Walter Ling, M.D. | Friends Research Institute, Inc. |
Publications:
ClinicalTrials.gov Identifier: | NCT00000298 History of Changes |
Other Study ID Numbers: |
NIDA-09260-1 P50-09260-1 |
First Posted: | September 21, 1999 Key Record Dates |
Last Update Posted: | August 17, 2005 |
Last Verified: | January 1996 |
Opioid-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone Analgesics, Opioid |
Narcotics Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents Narcotic Antagonists |